Neurocrine Biosciences and Rhythm are both targeting the rare obesity market.
1 report, 1 independent
Updated Sep 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Neurocrine Biosciences and Rhythm are both targeting the rare obesity market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.
-
Rhythm
Japanese global corporate group based in Saitama, Japan